Norris Medicines Complete Financial Statements
In FYNone, Norris Medicines (NORRIS) reported revenue ₹10 Cr, net profit ₹-1 Cr and EPS ₹-0.60, with a net profit margin of -16.7%. Full financial statements from FY2015 to FY2025 (11 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Review Norris Medicines price earnings to evaluate earnings-based valuation against sector peers.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
NORRIS Revenue, Net Profit & EBITDA — Year-on-Year Growth
NORRIS YoY (March 2025 vs Period) — revenue +66.7%, expenses +50.0%. Explore NORRIS Benjamin Graham valuation to estimate fundamental worth using multiple valuation models.
NORRIS Income Statement — Revenue, EBITDA & Net Profit
Norris Medicines revenue ₹10 Cr, EBITDA ₹0 Cr, net profit ₹-1 Cr, EPS ₹-0.60 (None) — net profit margin -16.7%. For live price, earnings ratios and company overview, see Norris Medicines share price screener.
| Particulars | None | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10 | 6 | 6 | 8 | 10 | 12 | 8 | 16 | 14 | 21 | 19 | 19 |
| Expenses | 9 | 6 | 6 | 7 | 10 | 14 | 10 | 17 | 16 | 21 | 18 | 17 |
| EBITDA | 0 | 0 | 0 | 1 | 0 | -2 | -2 | -1 | -2 | 0 | 1 | 2 |
| Operating Profit Margin % | 0.00% | -5.00% | -3.00% | 11.00% | -1.00% | -14.00% | -27.00% | -4.00% | -14.00% | 0.00% | 4.00% | 9.00% |
| Depreciation | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 1 | 0 | 0 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit Before Tax | -1 | -1 | -1 | -1 | -2 | -4 | -4 | -2 | -3 | -1 | 0 | 0 |
| Tax | 0 | 0 | 0 | 1 | 1 | 1 | -1 | 0 | -1 | 0 | 0 | 1 |
| Net Profit | -1 | -1 | -1 | -2 | -3 | -5 | -3 | -2 | -3 | -1 | 0 | -1 |
| Earnings Per Share (₹) | -0.60 | -1.24 | -1.19 | -1.75 | -3.26 | -4.96 | -2.84 | -1.68 | -2.51 | -0.77 | 0.04 | -1.04 |
NORRIS Balance Sheet — Assets, Liabilities & Shareholders' Equity
NORRIS total assets ₹14 Cr, total equity ₹-15 Cr, total liabilities ₹ Cr (2025).
| Particulars | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Total Assets | 14 | 14 | 14 | 14 | 20 | 21 | 20 | 21 | 22 | 18 | 18 |
| Current Assets | 6 | 6 | 5 | 4 | 8 | 7 | 7 | 8 | 9 | 7 | 7 |
| Fixed Assets | 5 | 6 | 7 | 7 | 8 | 8 | 9 | 9 | 10 | 8 | 9 |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 9 | 8 | 7 | 7 | 12 | 12 | 12 | 11 | 12 | 10 | 10 |
| LIABILITIES | |||||||||||
| Total Liabilities | |||||||||||
| Current Liabilities | 19 | 19 | 18 | 18 | 16 | 15 | 11 | 8 | 8 | 8 | 8 |
| Non-Current Liabilities | |||||||||||
| SHAREHOLDERS' EQUITY | |||||||||||
| Total Equity | -15 | -14 | -12 | -11 | -7 | -3 | 0 | 2 | 5 | 5 | 5 |
| Share Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves & Surplus | -25 | -24 | -22 | -21 | -17 | -12 | -10 | -8 | -5 | -5 | -5 |
NORRIS Cash Flow Statement — Operating, Investing & Financing
Norris Medicines operating cash flow ₹1 Cr, investing ₹0 Cr, financing ₹-1 Cr, net cash flow ₹0 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 1 | 0 | 1 | -1 | 1 | -3 | -2 | 1 | -1 | 1 | -1 |
| Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2 | 0 | -1 |
| Financing Activities | -1 | 0 | -1 | 1 | -1 | 3 | 2 | -1 | 3 | -1 | 0 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2 |